Medical Device Regulatory Updates: Key Legal Developments for 2025
Created on 07.06
Medical Device Regulatory Updates: Key Legal Developments for 2025
The landscape of medical device regulation is evolving at a pace that demands constant vigilance from manufacturers, contract research organizations, and healthcare providers alike. In 2025, new FDA guidance documents, heightened enforcement actions, and shifting compliance obligations are reshaping how companies bring devices to market and maintain post-market surveillance. For businesses such as HuaTeng Biotechnology, a preclinical CRO offering GLP-compliant and AAALAC-accredited services for medical device and drug development, understanding these changes is critical to supporting clients through safe and legally sound product launches. Whether you are navigating the 21 CFR 820 quality system requirements, aligning with MHRA medical device standards in the UK, or adapting to the EU MDR regulation, staying ahead of regulatory trends is no longer optional—it is a strategic imperative. This article provides a detailed examination of the most significant legal developments affecting the medical device industry in 2025, drawing on key FDA guidance updates, enforcement trends, fraud cases, and compliance best practices. By the end, you will have a clearer roadmap for managing risk and capitalizing on new regulatory pathways.
I. Introduction to Recent Medical Device Regulatory Landscape
A. Importance of Staying Informed on Legal Developments
The medical device regulatory environment is subject to rapid shifts driven by technological innovation, public health priorities, and congressional mandates. In 2025, the FDA has accelerated its release of draft and final guidance documents covering cybersecurity, digital health, real-world evidence, and machine learning. At the same time, the Department of Justice continues to pursue aggressive False Claims Act settlements and criminal prosecutions related to device fraud. For device companies, failure to monitor these developments can result in warning letters, civil monetary penalties, or even exclusion from federal healthcare programs. A proactive approach—one that integrates legal counsel and regular regulatory monitoring—helps organizations adapt their quality management systems, labeling, and clinical trial protocols before issues escalate. This is especially relevant for firms working with global regulatory bodies, where alignment with the EU MDR regulation and MHRA medical device standards is necessary for market access.
B. Overview of Key Areas: FDA Guidance, Enforcement, Fraud, and Compliance
This article covers four main pillars of the medical device regulatory landscape in 2025. First, we examine the most impactful FDA guidance updates, including cybersecurity requirements for connected devices, digital health technologies for clinical trials, real-world evidence frameworks, and the transition to mandatory electronic 510(k) submissions via eSTAR. Second, we analyze recent enforcement actions and fraud cases, highlighting trends in False Claims Act litigation, kickback schemes involving durable medical equipment, and criminal penalties for reuse of single-use devices. Third, we explore compliance and legal considerations such as Unique Device Identifier (UDI) enforcement, clinical trial data integrity, informed consent obligations, and export controls on medical technology. Finally, we address industry-specific topics like ethylene oxide sterilization regulation, laboratory developed tests, and Medicare coverage for breakthrough devices. Each section provides actionable insights grounded in the latest regulatory publications and legal precedents.
II. FDA Guidance Updates
A. Cybersecurity for Medical Devices: Comprehensive Guidance
The FDA has finalized its comprehensive guidance on cybersecurity for medical devices, requiring manufacturers to submit a cybersecurity bill of materials and a plan for coordinated vulnerability disclosure as part of premarket submissions. This guidance, aligned with the 2023 omnibus legislation, applies to any device with software, firmware, or programmable logic. Manufacturers must now demonstrate that their devices are designed to resist cybersecurity threats throughout their lifecycle, including post-market patches and updates. For companies engaging in Medical Device Testing In Vivo, this means integrating cybersecurity risk assessments into the preclinical testing phase to ensure that data integrity and patient safety are maintained from bench to bedside. The guidance also recommends adopting the NIST Cybersecurity Framework and participating in the FDA's Postmarket Management of Cybersecurity in Medical Devices program.
B. Digital Health Technologies for Remote Data Acquisition in Trials
In 2025, the FDA published a final guidance on the use of digital health technologies for remote data acquisition in clinical investigations. This document provides recommendations for sponsors using wearables, mobile apps, and remote sensors to collect safety and effectiveness data outside traditional clinical settings. The guidance covers considerations for device validation, data integrity, patient privacy, and informed consent in decentralized trial designs. For contract research organizations like HuaTeng Biotechnology, which supports preclinical and early-phase studies, understanding these digital endpoints is becoming increasingly important as sponsors seek to reduce trial costs and accelerate enrollment. The guidance emphasizes that digital health technologies must be qualified for their intended use, and that sponsors should document how they will handle missing data, device malfunctions, and subject non-compliance in remote settings.
C. Real-World Evidence in Device Regulatory Decisions
The FDA continues to expand its use of real-world evidence to support medical device regulatory decisions, including premarket approval, 510(k) clearance, and post-market surveillance. In 2025, the agency released updated guidance on the use of real-world data from registries, electronic health records, and claims databases to supplement traditional clinical trials. The guidance clarifies the agency's expectations for data quality, study design, and statistical analysis when real-world evidence is submitted in support of a regulatory decision. Manufacturers should be aware that the FDA may require a prospective study design even when real-world data are used, and that transparency in data provenance and analytical methods is essential. This shift toward real-world evidence aligns with global trends under the EU MDR regulation, where post-market clinical follow-up and real-world data are increasingly mandated for maintaining CE marking.
D. 510(k) Third Party Review Program Updates
The FDA has updated its 510(k) Third Party Review Program, expanding the list of accredited third-party organizations that can review certain low- to moderate-risk device submissions. This program allows manufacturers to submit their 510(k) applications to an accredited third-party reviewer rather than directly to the FDA, potentially reducing review times. In 2025, the FDA added new review organizations and clarified the scope of devices eligible for third-party review, excluding certain device types that require special expertise or have novel characteristics. Manufacturers should evaluate whether their device qualifies for this program and, if so, consider engaging an accredited reviewer to accelerate time to market. However, the FDA retains the authority to conduct a substantive review of any third-party decision, and manufacturers must still comply with all applicable quality system requirements under 21 CFR 820.
E. eSTAR Mandatory Electronic Submission for 510(k)
As of October 2024, the FDA made the electronic Submission Template and Resource (eSTAR) mandatory for all 510(k) submissions. This web-based tool guides applicants through the submission process, ensuring that all required elements are included and reducing the likelihood of deficiency holds. In 2025, the FDA has continued to refine the eSTAR platform, adding new modules for emerging device types and integrating with the agency's overall data management system. Manufacturers must now use eSTAR for all 510(k) submissions, and the FDA will not accept paper or PDF submissions unless a waiver has been granted. The transition to eSTAR aligns with the agency's broader digital transformation goals and is expected to improve submission quality and review consistency. Device companies should ensure that their regulatory teams are trained on eSTAR and that their internal processes are updated to capture the information required by the template.
F. Predetermined Change Control Plans for Machine Learning
In a landmark move, the FDA has finalized guidance on Predetermined Change Control Plans (PCCPs) for machine learning-enabled medical devices. A PCCP allows manufacturers to describe anticipated modifications to a device's algorithm—including changes to performance, inputs, outputs, or clinical indications—in the premarket submission, so that future modifications can be implemented without requiring a new 510(k) or PMA supplement. The guidance specifies what information must be included in a PCCP, including a description of the types of changes, the methodology for validating those changes, and an impact assessment. This framework is designed to accommodate the iterative nature of machine learning while maintaining safety and effectiveness. For companies developing AI-based diagnostic tools, the PCCP pathway represents a significant regulatory innovation that can reduce the burden of repeated submissions and accelerate the pace of improvement.
G. Good Clinical Practices Incorporating ICH E6(R3)
The FDA has updated its guidance on Good Clinical Practices to incorporate the International Council for Harmonisation's E6(R3) principles, which emphasize risk-based monitoring, quality by design, and patient engagement. This update applies to all clinical investigations of medical devices, including those conducted under IDE regulations. The revised GCP framework encourages sponsors to focus on critical data elements and processes that are most likely to affect subject safety and data integrity, rather than applying a one-size-fits-all monitoring approach. For organizations like HuaTeng Biotechnology that provide CRO Services, aligning internal standard operating procedures with ICH E6(R3) is essential for maintaining sponsor confidence and regulatory compliance. The guidance also includes new provisions for electronic records and signatures, reflecting the increased use of digital tools in clinical research.
III. Enforcement Actions and Fraud Cases
A. False Claims Act Settlements: Examples and Trends
The Department of Justice continues to use the False Claims Act as a primary tool to combat fraud in the medical device industry. In 2025, several high-profile settlements have involved allegations of off-label marketing, payment of kickbacks to physicians, and submission of false claims for devices that were not medically necessary. One notable case involved a spinal implant manufacturer that paid over $150 million to resolve allegations that it induced surgeons to use its products through consulting fees and travel payments. These settlements often include not only financial penalties but also corporate integrity agreements that require independent monitoring and reporting. Device companies should ensure that their sales and marketing practices are carefully documented and that all promotional claims are consistent with the device's cleared or approved indications. The False Claims Act also imposes liability on individuals, including corporate officers who knowingly approve fraudulent conduct.
B. Kickback Schemes and Telemedicine Fraud Involving DME
Telemedicine fraud involving durable medical equipment has become a major enforcement priority for the DOJ and HHS-OIG. In these schemes, telemedicine companies pay recruiters to identify Medicare beneficiaries, then arrange for a physician to order expensive devices—such as back braces, orthotics, or glucose monitors—without any genuine patient-physician relationship. The equipment suppliers then bill Medicare for devices that were never needed or requested by the patient. In 2025, federal prosecutors have charged dozens of individuals and companies with violations of the Anti-Kickback Statute and the False Claims Act in connection with such arrangements. Device manufacturers should be aware of the risks associated with selling to telemedicine providers and should implement robust compliance programs to verify that orders are based on legitimate medical need and that no illegal inducements are offered to referral sources.
C. Unapproved Device Marketing: FDA Warning Letters
The FDA continues to issue warning letters to companies marketing unapproved or misbranded medical devices. In 2025, the agency has targeted devices that make unsubstantiated claims related to cancer treatment, pain management, and diagnostic accuracy. For example, the FDA warned a manufacturer of a device that claimed to detect cancer through electrical impedance, finding that the device was neither cleared nor approved for marketing. The warning letters typically require the company to cease distribution, correct the labeling, and submit a regulatory application if the device qualifies for market authorization. Failure to respond adequately can lead to seizure, injunction, or civil money penalties. Device companies should conduct regular labeling audits and ensure that all promotional materials are reviewed by regulatory and legal teams before release.
D. Reuse of Single-Use Devices: Criminal Penalties
The reuse of single-use medical devices continues to attract criminal enforcement, particularly when reprocessed devices are sold without proper clearance or when patients are harmed as a result. In a recent case, the CEO of a reprocessing company was sentenced to prison for distributing single-use cardiac catheters that were cleaned and repackaged without FDA clearance, leading to patient infections. The FDA has established a regulatory framework for reprocessing of single-use devices, but companies must comply with premarket submission requirements and quality system regulations under 21 CFR 820. Enforcement actions in this area highlight the serious legal risks associated with unauthorized reprocessing and the importance of clear labeling and traceability. Manufacturers should also consider the potential liability if their devices are reused contrary to labeling, and may wish to implement design features that discourage reuse.
E. Corporate Officer Liability (Park Doctrine)
The Park Doctrine, which allows the FDA to hold corporate officers personally liable for violations of the Federal Food, Drug, and Cosmetic Act, remains a powerful enforcement tool in 2025. Under this doctrine, a responsible corporate official can be prosecuted even without proof that they personally committed or knew about the violation—it is enough that they had authority to prevent or correct the violation and failed to do so. Recent criminal prosecutions have targeted CEOs and quality assurance directors of device companies that distributed adulterated or misbranded products. For device company leaders, the Park Doctrine underscores the importance of implementing effective compliance and quality systems, maintaining accurate records, and fostering a culture of accountability. Personal liability cannot be delegated, and ignorance of the law is not a defense.
IV. Compliance and Legal Considerations
A. Unique Device Identifier (UDI) Enforcement
The FDA's Unique Device Identifier system is now fully operational, and enforcement actions are increasing for non-compliance. Under the UDI rule, manufacturers of most medical devices must label each device and its packaging with a UDI, and submit device information to the Global Unique Device Identification Database (GUDID). In 2025, the FDA has issued warning letters to companies that failed to assign UDIs to their devices or that submitted incorrect or incomplete data to GUDID. The UDI system is critical for post-market surveillance, adverse event reporting, and recall management, and non-compliance can lead to device misbranding charges. Manufacturers should ensure that their UDI processes are integrated into their quality management systems and that labelers are trained on format and placement requirements. The UDI also plays a role in supply chain transparency and is increasingly required by group purchasing organizations and healthcare systems.
B. Clinical Trial Fraud and Data Integrity
Clinical trial fraud remains a significant focus for FDA and DOJ enforcement, particularly when device companies manipulate data or fail to report adverse events. In 2025, a medical device company was ordered to pay $40 million to resolve allegations that it falsified data in a clinical study supporting a premarket approval application. The case involved fabricated patient records and altered test results. Beyond financial penalties, individuals involved in clinical trial misconduct may face exclusion from future research activities, debarment from FDA service, and criminal prosecution. For companies conducting device trials, maintaining data integrity requires rigorous source document verification, proper investigator training, and independent monitoring. Organizations like HuaTeng Biotechnology that support preclinical and clinical research must adhere to Good Laboratory Practices and Good Clinical Practices to ensure that data submitted to regulatory authorities are accurate and reliable.
C. Informed Consent and IRB Responsibilities
Informed consent requirements for medical device clinical trials continue to evolve, with increasing emphasis on patient comprehension and transparency. In 2025, the FDA updated its guidance on informed consent to include provisions for electronic consent, multimedia materials, and the use of plain language summaries. Institutional Review Boards are also under scrutiny, with the FDA issuing warning letters to IRBs that failed to properly review device trials or that had conflicts of interest. Device sponsors should ensure that their consent forms include all required elements, such as a description of the device, its risks and benefits, alternative treatments, and contact information for questions. For digital health devices that collect personal health information, additional disclosures about data sharing and privacy are necessary to meet both FDA requirements and the Health Breach Notification Rule.
D. Health Breach Notification Rule for Digital Health
The Federal Trade Commission's Health Breach Notification Rule applies to digital health apps and connected devices that collect or store personal health records. In 2024 and 2025, the FTC has actively enforced this rule against companies that failed to notify consumers of data breaches involving health information. The rule applies to vendors of personal health records and third-party service providers, requiring them to notify consumers, the FTC, and in some cases the media when unsecured identifiable health information is breached. For medical device manufacturers that offer companion apps or cloud-based data platforms, compliance with this rule is essential. The FTC has made clear that it considers the unauthorized disclosure of health information—even through tracking pixels or analytics tools—to be a breach warranting notification. Companies should conduct privacy impact assessments and implement robust data security measures to prevent breaches.
E. Export Controls on Medical Device Technology
Export controls on medical device technology have tightened in 2025, with the Bureau of Industry and Security adding certain biotechnology and medical device-related technologies to the Commerce Control List. These controls affect the export of specialized laboratory equipment, genetic sequencing devices, and certain software used for medical diagnostics. Companies that manufacture, distribute, or license such technologies must determine whether an export license is required before sharing technical data with foreign entities, including contract research organizations and academic collaborators. Violations of export control regulations can result in substantial fines, denial of export privileges, and criminal liability. Device companies should establish internal export compliance programs, screen all international transactions, and classify their products under the appropriate Export Control Classification Number (ECCN) to ensure that they are not inadvertently transferring controlled technology to unauthorized recipients.
V. Industry-Specific Topics
A. Ethylene Oxide Sterilization Regulations (EPA)
The Environmental Protection Agency has proposed tighter restrictions on ethylene oxide emissions from commercial sterilizers, which could affect medical device manufacturers that rely on EtO for sterilization of their products. The proposed rule would require sterilizer facilities to install emission control technology, monitor ambient levels of EtO, and reduce worker exposure to levels that minimize cancer risk. For device companies, this could mean longer sterilization cycles, higher costs, and potential disruptions to the supply chain if sterilizer facilities are forced to temporarily close for upgrades. Companies should explore alternative sterilization methods, such as gamma irradiation, electron beam, or vaporized hydrogen peroxide, and should engage with contract sterilizers to understand their compliance plans. The FDA has stated that it will work with manufacturers to ensure that sterilization changes do not adversely affect device safety or availability.
B. Laboratory Developed Tests (LDTs) Proposed Rule
The FDA has proposed a rule that would subject laboratory developed tests to the same medical device regulatory requirements as commercial in vitro diagnostics. Under the proposed framework, LDTs would be phased into FDA oversight over several years, with high-risk LDTs—such as those used for cancer diagnosis or genetic screening—subject to premarket review first. This change would have significant implications for hospital labs, academic medical centers, and commercial reference laboratories that develop and perform LDTs. Device companies that manufacture components or reagents used in LDTs should monitor the rule's progress and consider how it might affect their customer base and product labeling. The proposed rule also raises questions about the integration of LDTs with digital health platforms and the role of real-world data in supporting test performance claims.
C. Medicare Coverage of Breakthrough Devices
In 2025, the Centers for Medicare & Medicaid Services has expanded coverage pathways for breakthrough medical devices that have received FDA Breakthrough Device designation. Under the new Medicare Coverage of Innovative Technology (MCIT) paradigm, certain breakthrough devices may qualify for national coverage immediately upon FDA approval or clearance, rather than waiting for local coverage determinations. This policy is intended to accelerate patient access to cutting-edge technologies in areas such as neurology, cardiology, and oncology. Device manufacturers with breakthrough designation should work closely with CMS to understand the evidence requirements for coverage and to ensure that their billing and coding submissions are accurate. The expanded coverage pathway also creates opportunities for companies to gather real-world evidence through routine clinical use, which can support broader coverage expansion over time.
D. FDA Enforcement Policy for Non-Invasive Monitoring Devices
The FDA has issued an enforcement policy for non-invasive remote monitoring devices that are used to measure vital signs, activity levels, and physiological parameters in home or ambulatory settings. Under this policy, the FDA will not enforce premarket review requirements for certain low-risk monitoring devices that meet specific criteria, including limitations on the types of measurements made, the populations for whom the device is intended, and the labeling claims that can be made. However, manufacturers must still comply with registration and listing requirements, quality system regulations under 21 CFR 820, and adverse event reporting. This guidance is particularly relevant for companies developing consumer wellness devices that blur the line between general wellness and medical use. Manufacturers should carefully evaluate whether their device falls within the scope of the enforcement policy or whether a 510(k) submission is required based on the intended use and technological characteristics.
VI. Conclusion and Best Practices
A. Proactive Compliance Strategies for Device Companies
Navigating the complex medical device regulatory landscape in 2025 requires a proactive and integrated approach to compliance. Device companies should establish cross-functional regulatory teams that include legal, quality, clinical, and engineering expertise to monitor regulatory developments and assess their impact on existing and planned products. Regular training on FDA guidance updates, enforcement trends, and quality system requirements under 21 CFR 820 should be provided to all relevant personnel. For organizations like HuaTeng Biotechnology, which offers Resources for preclinical research, maintaining strong partnerships with experienced regulatory consultants and legal counsel can help device sponsors avoid costly missteps. Additionally, investing in robust data management systems that support UDI compliance, electronic submissions, and real-world evidence collection will position companies for success in an increasingly digital regulatory environment.
B. Importance of Legal Counsel and Regulatory Monitoring
Given the pace of change in medical device regulation, from the EU MDR regulation to MHRA medical device standards to FDA enforcement priorities, regular engagement with specialized legal counsel is essential. Attorneys with experience in FDA law, fraud and abuse, and export controls can provide targeted advice on risk mitigation strategies, internal investigations, and regulatory submissions. Device companies should also subscribe to FDA email alerts, attend industry conferences, and participate in trade association working groups to stay ahead of emerging issues. By combining internal expertise with external legal and regulatory support, organizations can not only avoid enforcement actions but also identify strategic opportunities to accelerate approvals, expand market access, and differentiate themselves in a competitive landscape. The cost of non-compliance—measured in fines, reputational damage, and lost market share—far exceeds the investment in a robust compliance program.
Frequently Asked Questions (FAQ)
1. What is the most important medical device regulatory update for 2025?
The most significant update is the FDA's final guidance on cybersecurity for medical devices, which requires manufacturers to submit a cybersecurity bill of materials and a vulnerability disclosure plan as part of premarket submissions. This applies to all devices with software, firmware, or programmable logic, and represents a fundamental shift toward lifecycle security management. Additionally, the mandatory use of eSTAR for 510(k) submissions and the expansion of Predetermined Change Control Plans for machine learning devices are critical developments that affect most device companies.
2. How does the 21 CFR 820 quality system regulation relate to current medical device compliance?
The 21 CFR 820 quality system regulation, now aligned with ISO 13485, remains the backbone of medical device compliance in the United States. It requires manufacturers to establish and maintain a quality management system covering design controls, production, labeling, and corrective actions. In 2025, FDA enforcement continues to focus on quality system deficiencies, particularly in areas such as supplier management, risk assessment, and complaint handling. Compliance with 21 CFR 820 is also a prerequisite for marketing devices that rely on real-world evidence or digital health technologies.
3. What are the key differences between MHRA medical device requirements and FDA requirements?
The MHRA medical device regulations in the UK are largely aligned with the EU MDR regulation but include UK-specific post-market surveillance and registration requirements. Unlike the FDA, which uses a risk-based classification system with 510(k) and PMA pathways, the MHRA relies on UK Approved Bodies for conformity assessment. In 2025, the MHRA is developing its own framework for software as a medical device and digital health technologies, which may diverge from FDA guidance in areas such as clinical evidence requirements and cybersecurity expectations. Device companies marketing in both jurisdictions must prepare separate submissions and maintain compliance with two distinct regulatory systems.
4. How does the EU MDR regulation affect device companies outside Europe?
The EU MDR regulation has extraterritorial effect because it requires any device marketed in the European Union—regardless of where it is manufactured—to comply with its requirements for clinical evaluation, post-market surveillance, and labeling. In 2025, many non-European companies are still struggling with the transition from the Medical Device Directive to the MDR, particularly in areas such as clinical investigation requirements and the need for a Person Responsible for Regulatory Compliance. The MDR also places greater emphasis on transparency through the European Database on Medical Devices (EUDAMED), which includes publicly available information on device certification and clinical studies.
5. What enforcement trends should medical device companies watch for in 2025?
The most prominent enforcement trends include increased False Claims Act settlements for off-label marketing and kickback schemes, criminal prosecutions under the Park Doctrine for corporate officers, and FDA warning letters for unapproved device marketing. The DOJ is also focusing on telemedicine fraud involving durable medical equipment and on data integrity violations in clinical trials. Companies should expect continued scrutiny of quality system compliance, particularly in the areas of corrective and preventive actions and supplier controls. The use of data analytics by enforcement agencies is making it easier to detect patterns of fraudulent billing and non-compliance.
6. What are the compliance requirements for Unique Device Identifier implementation?
Under the FDA's UDI rule, manufacturers must label each device and its packaging with a UDI that includes a device identifier and a production identifier. They must also submit device information to the GUDID database, including the device's catalog number, brand name, and device description. In 2025, the FDA is actively enforcing UDI compliance, with warning letters issued for missing or inaccurate submissions. Manufacturers should integrate UDI creation and submission into their quality management system, ensure that labelers are properly trained, and verify that UDIs are correctly printed in both human-readable and machine-readable formats.
7. How can device companies protect themselves from liability under the Park Doctrine?
To mitigate Park Doctrine liability, corporate officers must demonstrate that they have exercised responsible oversight of manufacturing quality and regulatory compliance. This includes establishing clear policies and procedures, delegating authority to qualified personnel, monitoring compliance through audits and metrics, and taking prompt corrective action when problems are identified. Officers should document their oversight activities and ensure that they are not willfully ignorant of violations. Regular training on FDA regulations, internal reporting mechanisms, and a culture of transparency are essential components of a robust compliance program that can serve as a defense against personal liability.
8. What are the best practices for conducting preclinical testing in compliance with current regulations?
Best practices for preclinical testing include conducting studies in accordance with Good Laboratory Practices, using animal models that are appropriate for the device's intended use, and ensuring that all testing protocols are reviewed by an Institutional Animal Care and Use Committee. For companies working with partners like HuaTeng Biotechnology, which offers Animal Models and GLP-compliant services, it is important to verify that the CRO is AAALAC-accredited and that its facilities meet the required standards. Data integrity is critical, so all findings should be documented in a raw data archive, and electronic records should be managed in accordance with 21 CFR Part 11. Early engagement with regulatory consultants can help ensure that the preclinical strategy aligns with the expectations of FDA, MHRA, or other regulatory bodies.
9. How do export controls affect medical device technology in 2025?
Export controls now cover a broader range of medical device technologies, including certain laboratory equipment, genetic testing devices, and software for medical diagnostics. Companies must determine the ECCN for their products and obtain an export license from the BIS if required before sharing technical data with foreign entities. Violations can lead to significant fines and denial of export privileges. Device companies should implement export compliance screening procedures, train employees on controlled technology handling, and include export control clauses in contracts with overseas CROs and distributors. The tightening of export controls also affects the ability to collaborate with foreign research institutions on emerging technologies.
10. What resources are available to help device companies stay current with regulatory changes?
Device companies can access a wealth of resources to stay current, including the FDA's email notification system for guidance documents and enforcement actions, the CDRH Learn online training platform, and industry publications such as the Medical Device & Diagnostic Industry newsletter. Trade associations like AdvaMed and the Medical Device Manufacturers Association offer working groups and webinars focused on regulatory policy. For companies seeking hands-on support, partnering with a CRO that offers comprehensive Medical Device Testing In Vivo and regulatory guidance can provide practical insights into compliance challenges. Additionally, legal counsel with FDA expertise can offer targeted advice on submissions, enforcement risk, and global regulatory strategies.
Contact
Leave your information and we will contact you.
Copyright ©️ 2022, NetEase Zhuyou(and its affiliates as applicable). All Rights Reserved.
Company
Company
Collections
Collections
About
About
Follow us
Follow us
Team&Conditions
Work With Us
Featured Products
News
All products
Shop
phone
Email